Evidence map›Paper›PMID 31608139›Full record

ArticleOncotarget2019

Impact of exosomal HIV-1 Tat expression on the human cellular proteome.

Huafei Lu, Xiaoli Tang, Mitchell Sibley, Jillian Coburn, R Shyama Prasad Rao, Nagib Ahsan, Bharat Ramratnam

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Huafei LuDivision of Infectious Diseases, Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
Xiaoli TangDivision of Infectious Diseases, Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
Mitchell SibleyDivision of Infectious Diseases, Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
Jillian CoburnCOBRE Center for Cancer Research Development, Proteomics Core Facility, Rhode Island Hospital, Providence, RI 02903, USA.
R Shyama Prasad RaoBiostatistics and Bioinformatics Division, Yenepoya Research Center, Yenepoya University, Mangalore 575018, India.
Nagib AhsanCOBRE Center for Cancer Research Development, Proteomics Core Facility, Rhode Island Hospital, Providence, RI 02903, USA.
Bharat RamratnamDivision of Infectious Diseases, Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
Brown University · USCenter for Cancer Research · USProvidence College · USRhode Island Hospital · USYenepoya University · IN

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
Tracking and Evaluation CoreU54GM115677 · NIGMS · BROWN UNIVERSITY · PI ROUNDS, SHARON IRENE SMITH · 2016 to 2025
$45.0M
COBRE Center for Cancer Research DevelopmentP30GM110759 · NIGMS · RHODE ISLAND HOSPITAL · PI RAMRATNAM, BHARAT · 2015 to 2019
$6.3M
Next-generation extracellular vesicle biologics to target central nervous system and peripheral reservoirs of HIVR01AI144997 · NIAID · JOHNS HOPKINS UNIVERSITY · PI RAMRATNAM, BHARAT, WITWER, KENNETH W · 2019 to 2023
$4.0M
Studies in HIV-1 Pathogenesis and TransmissionK24HD080539 · NICHD · RHODE ISLAND HOSPITAL · PI RAMRATNAM, BHARAT · 2014 to 2018
$807k
NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI144997NICHD NIH HHS K24 HD080539NIGMS NIH HHS P30 GM110759NIGMS NIH HHS U54 GM115677
6 · The paper itself

Abstract

HIV-1 exists in a latent form in all infected patients. When antiretroviral therapy is stopped, viral replication resumes. The HIV-1 Tat protein is a potent activator of viral transcription. Our previous work has demonstrated that exosomal formulations of Tat can reverse HIV-1 latency in primary CD4+ T lymphocytes isolated from long term antiretroviral treated individuals suggesting a potential role for Tat as a therapeutic HIV-1 Latency Reversal Agent (LRA). Here, we employed the label-free proteomic approach for profiling the proteomic changes associated with exosomal Tat production in human cell lines. Comparative proteomic analysis revealed that >30% peptides were differentially expressed in abundance in the Tat-expressing cell line compared with relevant controls. As expected, many of the known Tat-interactor proteins were upregulated. Tat expression also led to the upregulation of antioxidant proteins suggesting Tat-mediates an oxidative burst. Gene ontology and pathway analyses of these differentially expressed proteins showed enrichment of extracellular vesicular exosome and spliceosome localized proteins and proteins involved with transcriptional and translational mechanisms. Our work suggests that HIV-1 Tat expression leads to perturbations in cellular protein expression.

Indexed as

exosomeHIV-1label-free proteomicsROStat protein

Identifiers

PMID31608139
PMCPMC6771461
OpenAlexW2980606805

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.